Showing 2191-2200 of 3223 results for "".
- Jury Awards Allergan Just $48,500 in Trial Over Imprimis False Adshttps://modernod.com/news/jury-awards-allergan-just-48500-in-trial-over-imprimis-false-ads/2476595/A California federal jury ordered Imprimis Pharmaceuticals to pay Allergan for lost profits due to false advertising of its compounded drugs. However, the jury awarded just $48,500 in damages, a small fraction of the millions of dollars that Allergan was seeking. According to a
- Alcon Reports First Quarter 2019 Trading Updatehttps://modernod.com/news/alcon-reports-first-quarter-2019-trading-update/2476592/Alcon reported selected financial results for the first quarter ending March 31, 2019, and provided financial guidance for the current fiscal year. For the first quarter of 2019, worldwide net sales were $1.8 billion, flat on a reported basis and an increase of 4 percent on a constant currency ba
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- FDA Approves Eylea for All Stages of Diabetic Retinopathyhttps://modernod.com/news/fda-approves-eylea-for-diabetic-retinopathy/2476580/Regeneron announced that the FDA has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR). The FDA approval of Eylea as a treatment for DR was based on 6-month and 1-year results from PANORAMA, a randomized, multicenter, controlled phase 3 trial that enrolled 40
- Alcon Launches Advancements to the Centurion Vision System at ASCRShttps://modernod.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/Alcon introduced new phaco technology that is part of the Centurion Vision System, including the Active Sentry Handpiece and Intrepid Hybrid Tip, at the ASCRS annual meeting. These new products, which are designed to improve safety, consistency and control during cataract surgery,
- Ellex to Launch Innovative New Ultrasound Technology at ASCRShttps://modernod.com/news/ellex-to-launch-innovative-new-ultrasound-technology-at-ascrs/2476552/Ellex Medical Lasers announced the market launch of the company’s Eye Prime diagnostic ultrasound technology that is essential for evaluating pathology of the eye. FDA clearance was received on April 12, 2019. This proprietary diagnostic advance features a multifocal array of 6 focal point
- The Healthcare Alliance for Patient Safety Statement in Response to FTC Proposed Contact Lens Rulehttps://modernod.com/news/the-healthcare-alliance-for-patient-safety-statement-in-response-to-ftc-proposed-contact-lens-rule/2476553/The Healthcare Alliance for Patient Safety (Alliance) released the following statement in response to last week’s Federal Trade Commission (FTC) proposed supplemental rulemaking on the 2016 proposed Contact Lens Rule. Congress charged the FTC with enforcing contact lens prescription
- Alcon Highlights Offerings to Drive Practice Efficiency and Excellence at ASCRShttps://modernod.com/news/alcon-highlights-offerings-to-drive-practice-efficiency-and-excellence-at-ascrs/2476550/At the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, Alcon announced the expanded Activate Practice Optimization Program and the launch of the Wanda Alcon Inventory Manager radio-frequency identification (RFID) scanner. “Our work is fue
- Allergan to Present Two Podium Presentations on Bimatoprost Sustained-Release (SR) at ASCRShttps://modernod.com/news/allergan-to-present-two-podium-presentations-on-bimatoprost-sustained-release-sr-at-ascrs/2476546/Allergan will present new data for its investigational implant, Bimatoprost SR, and a late-breaking analysis on its subconjunctival gelatin implant, XEN Gel Stent, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, from
- Alcon to Showcase New Clinical Data, Innovative Technology at ASCRShttps://modernod.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/Alcon will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego. The company, which recently became an independ